Estonia Market Community

Cue Biopharma bets its future on a new allergy drug designed by the same scientist who created Xolair, aiming to make treatment far less frequent for people with chronic hives and other allergic conditions. A key mid-stage trial result is coming soon, and it could either put Cue on big pharma’s radar or expose just how risky this turnaround really is.

AST SpaceMobile is moving from demos to putting real satellites in orbit to bring phone service to regular smartphones in places where towers can’t reach. Big carrier tie-ups and early government work add credibility, but the plan still hinges on flawless launches and smooth rollout in a crowded satellite race.

A little-known step in making AI chips work at scale is turning into a bottleneck: stacking and checking chips and memory so they don’t fail. Onto Innovation may sit right in that chokepoint thanks to a key customer qualification and growing demand from AI memory makers, but delays, tougher competition, or export rules could still derail the story.

Nu Holdings takes a hit as Brazil’s economy weakens and loan losses rise, but the core idea stays the same: a branch-free bank that keeps gaining customers and selling them more services. The next chapters—getting bigger in Mexico, testing new AI-driven advice, and a possible move into the U.S.—could change how investors see the business, but there are real risks tied to Brazil and credit quality.